NK/T-CELL LYMPHOMA
Clinical trials for NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: TR115 faces off against standard care
Disease control Not yet recruitingThis study tests a new drug called TR115 in about 180 adults with a rare blood cancer (T/NK-cell lymphoma) that has come back or not responded to prior treatments. Participants will receive either TR115 or one of several standard drugs. The main goal is to see if TR115 can slow c…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Tarapeutics Science Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New vaccine aims to fight Hard-to-Treat EBV cancers
Disease control Not yet recruitingThis study tests a vaccine called KSD-101 in 80 people with blood cancers linked to the Epstein-Barr virus (EBV). The vaccine uses a patient's own immune cells to target EBV and cancer. Researchers want to see if it can shrink tumors or keep the disease from coming back.
Matched conditions: NK/T-CELL LYMPHOMA
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Triple-Drug attack aims to beat rare lymphoma
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—golidocitinib, pegaspargase, and an immunotherapy—as a first treatment for advanced NK T-cell lymphoma, a rare and aggressive cancer. The study will enroll 40 people who have not had prior therapy. The goal is to see if this c…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: LIANG WANG • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo before transplant aims to beat rare lymphoma
Disease control Not yet recruitingThis study tests a combination of three chemotherapy drugs (thiotepa, cyclophosphamide, and busulfan) given before a stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this approach helps keep the cancer from coming back. About 37 adults aged 18-70 who…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug combo aims to stop rare lymphoma from coming back after transplant
Disease control Not yet recruitingThis study tests whether a combination of two drugs, selinexor and azacitidine, can help prevent NK/T-cell lymphoma from returning after a stem cell transplant. About 39 adults aged 18-70 who have already received a transplant will take these drugs as maintenance therapy. The goa…
Matched conditions: NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC